Nicolab Wholesale Investment

Nicolab Investment Opportunity - Wholesale Only*

An exclusive opportunity for existing shareholders to invest in Nicolab’s growth opportunity in China.

Request an allocation

Wholesale Only*

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provide Corporate Advisory Services to Nico.Lab International Limited and will receive fees for its role in managing this offer based on the uptake by investors. Reach Wholesale Nominees Pty Ltd ATF Wholesale Holdings Nicolab Trust, a related entity of Reach Markets, holds stock or shares in Nico.Lab International Limited.

Close

Request Offer Docs

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provide Corporate Advisory Services to Nico.Lab International Limited and will receive fees for its role in managing this offer based on the uptake by investors.

Australian medtech Nicolab is entering one of the world’s largest healthcare markets.

Nicolab is entering China – one of the largest healthcare market on the planet where stroke is the leading cause of death. 

The Chinese government has been investing billions of dollars into stroke care, resulting in state-of-the art infrastructure (5G connectivity, CT availability), which lends itself to Nicolab’s advanced stroke analysis technology. China already has 1474 nominated stroke centers and is expected to triple this number by 2030.

Nicolab is now looking to leverage its existing product suite, regulatory clearances, and relationships to obtain market share in a short timeframe. The company is partnering with experts in medical research, neurological treatment, diagnostic imaging, and health data systems.

Nicolab is offering existing shareholders exclusively to invest directly (via a Reach Trust) in the local venture in order to benefit from the potential upside of this opportunity.

Hear more about the company

Latest Investor Briefing

CFO Charlie Bell explains Nicolab’s growth strategy and the structure of the investment.
31 mins | December, 2024

Company Presentation

 
9 pages | December, 2024

Investment Highlights

  • Exposure to Nicolab China via Reach Trust
  • $25,000 minimum bid – $100,000 maximum bid size
  • Semi-annual dividends envisaged from end of 2025
  • Exit option upon trade sale, share sale, IPO – with valuation floored at 2x and capped at 8x
  • In case oversubscriptions, allocations pro rata to bid size
  • Refer to Term Sheet for full explanation

Michael Macilquham

Chief Executive Officer

Michael is an accomplished business leader with a strong background in sales, marketing, and operations. As the CEO of Nicolab, he has been instrumental in shaping the company’s growth and strategic direction. Michael has also brought a disciplined approach to aligning Nicolab’s commercial strategy with its overall business direction and processes, ensuring a cohesive and focused path to success.

Prior to joining Nicolab, Michael held various leadership roles at Siemens Healthineers, where he played a key role in driving revenue growth, developing strategic partnerships, and launching innovative healthcare solutions. His extensive industry experience has enabled him to build successful teams and execute impactful initiatives.

Michael holds a Bachelor of Applied Science in Diagnostic Radiography and a Master of Health Science, majoring in Magnetic Resonance Imaging, from the University of Sydney.

Charlie Bell

Chief Financial Officer

Charlie is an Australian accountant specializing in financial reporting, governance, and stakeholder relations and management, with over ten years of experience in professional services working with pre-IPO, ASX-listed, and large private companies across multiple statutory jurisdictions.

Member of the Institute of Chartered Accountants Australia and New Zealand, Charlie holds a Bachelor of Commerce, majoring in Accountancy and Business Law.

Merel Boers, PhD

Founder & Director

Merel is a Dutch health tech entrepreneur with a medical technology background and a PhD in image analysis in stroke. One out of nine women ever to obtain the highest honors for her PhD research at the Technical University of Twente, Merel was awarded the Prof Vooijs award for the most clinically relevant research.

Focused on creating value and making a difference, Merel has a clear vision for the company and the role of AI in the emergency workflow.

A regular speaker at events hosted by Google, HPE and universities, in 2021 Merel has been awarded the EU Prize for Women Innovators in that year.

Razmara Nizak

Chief Technology Officer

Razmara is a technical physician with over ten years of experience in the medical health tech sector, specializing in leveraging technology to enhance healthcare. With a strong background in medical engineering, he has a proven ability to translate innovation and R&D into practical solutions that improve patient care and operational efficiency.

Razmara’s expertise includes developing and implementing scalable healthcare technologies, leading cross-functional teams, and navigating the complexities of healthcare IT systems with the goal to drive impactful innovations that address industry challenges

Michael Macilquham

Chief Executive Officer

Michael is an accomplished business leader with a strong background in sales, marketing, and operations. As the CEO of Nicolab, he has been instrumental in shaping the company’s growth and strategic direction. Michael has also brought a disciplined approach to aligning Nicolab’s commercial strategy with its overall business direction and processes, ensuring a cohesive and focused path to success.

Prior to joining Nicolab, Michael held various leadership roles at Siemens Healthineers, where he played a key role in driving revenue growth, developing strategic partnerships, and launching innovative healthcare solutions. His extensive industry experience has enabled him to build successful teams and execute impactful initiatives.

Michael holds a Bachelor of Applied Science in Diagnostic Radiography and a Master of Health Science, majoring in Magnetic Resonance Imaging, from the University of Sydney.

Charlie Bell

Chief Financial Officer

Charlie is an Australian accountant specializing in financial reporting, governance, and stakeholder relations and management, with over ten years of experience in professional services working with pre-IPO, ASX-listed, and large private companies across multiple statutory jurisdictions.

Member of the Institute of Chartered Accountants Australia and New Zealand, Charlie holds a Bachelor of Commerce, majoring in Accountancy and Business Law.

Merel Boers, PhD

Founder & Director

Merel is a Dutch health tech entrepreneur with a medical technology background and a PhD in image analysis in stroke. One out of nine women ever to obtain the highest honors for her PhD research at the Technical University of Twente, Merel was awarded the Prof Vooijs award for the most clinically relevant research.

Focused on creating value and making a difference, Merel has a clear vision for the company and the role of AI in the emergency workflow.

A regular speaker at events hosted by Google, HPE and universities, in 2021 Merel has been awarded the EU Prize for Women Innovators in that year.

Razmara Nizak

Chief Technology Officer

Razmara is a technical physician with over ten years of experience in the medical health tech sector, specializing in leveraging technology to enhance healthcare. With a strong background in medical engineering, he has a proven ability to translate innovation and R&D into practical solutions that improve patient care and operational efficiency.

Razmara’s expertise includes developing and implementing scalable healthcare technologies, leading cross-functional teams, and navigating the complexities of healthcare IT systems with the goal to drive impactful innovations that address industry challenges

Request an allocation

Wholesale Only*

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provide Corporate Advisory Services to Nico.Lab International Limited and will receive fees for its role in managing this offer based on the uptake by investors. Reach Wholesale Nominees Pty Ltd ATF Wholesale Holdings Nicolab Trust, a related entity of Reach Markets, holds stock or shares in Nico.Lab International Limited.

Reach Markets provide Corporate Advisory Services to Nico.Lab International Limited and will receive fees for its role in managing this offer based on the uptake by investors.

Reach Wholesale Nominees Pty Ltd ATF Wholesale Holdings Nicolab Trust, a related entity of Reach Markets, holds stock or shares in Nico.Lab International Limited.

*Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.

  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status.  Please refer to the Corporations Act:  Specifically Section 708(08) and Section s761G(7)

Any advice provided by Reach Markets, including on its website and by its representatives, is general advice only and does not consider your personal objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. You need to also read any relevant offer documents to understand the features, risks and returns associated with the investment to make your own informed decision.

Please click here to read our full general advice warning.

If you are thinking about acquiring a financial product, you should consider our Reach Markets Financial Services Guide (FSG) including the Privacy Statement.

Past performance is not a reliable indicator of future performance.